{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=79", "query": { "condition": "Immune Dysfunction", "page": 79 }, "page_size": 10 }, "pagination": { "page": 79, "page_size": 10, "total_count": 20623, "total_pages": 2063, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=80&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=78&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T10:51:39.113Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00324597", "title": "AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Lymphoma", "Lymphoproliferative Disorder", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "motesanib diphosphate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2005-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-17", "last_synced_at": "2026-10-31T10:51:39.113Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324597" }, { "nct_id": "NCT04052997", "title": "Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "Camidanlumab Tesirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ADC Therapeutics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 117, "start_date": "2019-09-13", "completion_date": "2023-01-19", "has_results": true, "last_update_posted_date": "2024-03-28", "last_synced_at": "2026-10-31T10:51:39.113Z", "location_count": 24, "location_summary": "Scottsdale, Arizona • Duarte, California • San Francisco, California + 19 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04052997" }, { "nct_id": "NCT04313582", "title": "Feasibility of the SmartPrompt for Improving Everyday Function in Dementia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dementia", "Dementia, Vascular", "Dementia Alzheimers", "Dementia, Mixed", "Dementia, Mild", "Dementia of Alzheimer Type", "Mild Cognitive Impairment", "Mild Dementia" ], "interventions": [ { "name": "SmartPrompt smartphone application", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Temple University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-03-13", "completion_date": "2023-04-01", "has_results": false, "last_update_posted_date": "2024-07-16", "last_synced_at": "2026-10-31T10:51:39.113Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04313582" }, { "nct_id": "NCT01711359", "title": "A Study in Participants With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Baricitinib Placebo", "type": "DRUG" }, { "name": "MTX Placebo", "type": "DRUG" }, { "name": "Folic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 588, "start_date": "2012-11", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2019-09-19", "last_synced_at": "2026-10-31T10:51:39.113Z", "location_count": 47, "location_summary": "Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "El Cajon", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01711359" }, { "nct_id": "NCT00885196", "title": "A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Moderate and Severe Plaque Psoriasis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "AEB071", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 336, "start_date": "2009-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-12-22", "last_synced_at": "2026-10-31T10:51:39.113Z", "location_count": 10, "location_summary": "Hot Springs, Arizona • Pinellas Park, Florida • Overland Park, Kansas + 6 more", "locations": [ { "city": "Hot Springs", "state": "Arizona" }, { "city": "Pinellas Park", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00885196" }, { "nct_id": "NCT03015896", "title": "Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Grade 3a Follicular Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Waldenstrom Macroglobulinemia", "Refractory Burkitt Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "David Bond, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2017-02-14", "completion_date": "2026-08-28", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-31T10:51:39.113Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Columbus, Ohio", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03015896" }, { "nct_id": "NCT06742996", "title": "A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mantle Cell Lymphoma", "B Cell Lymphoma" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2025-03-05", "completion_date": "2032-03-30", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-10-31T10:51:39.113Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06742996" }, { "nct_id": "NCT04400240", "title": "Care Coordination Approaches to Learning Lupus Self-management", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "CALLS", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-01-01", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2020-05-22", "last_synced_at": "2026-10-31T10:51:39.113Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04400240" }, { "nct_id": "NCT04118868", "title": "Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mycosis Fungoides" ], "interventions": [ { "name": "Pembrolizumab administered using the Sofusa® DoseConnect™", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Sorrento Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-08-31", "completion_date": "2024-03-27", "has_results": false, "last_update_posted_date": "2022-10-12", "last_synced_at": "2026-10-31T10:51:39.113Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04118868" }, { "nct_id": "NCT01950650", "title": "GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "No treatment given", "type": "BEHAVIORAL" }, { "name": "survey", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1800, "start_date": "2010-03", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2017-04-27", "last_synced_at": "2026-10-31T10:51:39.113Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01950650" } ] }